The prognostic impact of hormone receptors and c-erbB-2 in pregnancy-associated breast cancer and their correlation with BRCA1 and cell cycle modulators

International Journal of Surgical Pathology

Volumn 11, Issue 2, 2003, Pages 65-74

  Reed, Wenche ^a,b   Sandstad, Berit ^a   Holm, Ruth ^a   Nesland, Jahn M ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Breast cancer; C erbB 2; Cell cycle modulators; Hormone receptors; Pregnancy

Indexed keywords

CYCLIN D1; CYCLIN E; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN P27;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER SURVIVAL; CELL CYCLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; ONCOGENE; ONCOGENE C ERB; PREGNANCY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR VOLUME;

EID: 0037884717     PISSN: 10668969     EISSN: None     Source Type: Journal    
DOI: 10.1177/106689690301100201     Document Type: Article

References (61)

1. Wallack CK, Wolf JA, Denes AE, Glasgow G, Kumar B. Gestational carcinoma of the female breast. Curr Probl Cancer 7:1-58, 1983
2. Lethaby AE, O'Neill MA, Mason BH, Holdaway IM, Harvey VJ. Overall survival from breast cancer in women pregnant or lactating at or after diagnosis. Auckland Breast Cancer Study Group. Int J Cancer 67:751-755, 1996
3. Kollias J, Elston CW, Ellis IO, Robertson JF, Blamey RW. Early-onset breast cancer - histopathological and prognostic considerations. Br J Cancer 75:1318-1323, 1997
4. Bonnier P, Romain S, Dilhuydy JM, Bonichon F, Julien JP, Charpin C, Lejeune C, Martin PM, Piana L. Influence of pregnancy on the outcome of breast cancer: A case-control study. Int J Cancer 72:720-727, 1997
5. Tretli S, Kvalheim G, Thoresen S, Host H. Survival of breast cancer patients diagnosed during pregnancy or lactation. Br J Cancer 58:382-384, 1988
6. Marquis ST, Rajan JV, Wynshaw-Boris A, Xu J, Yin GY, Abel KJ, Weber BL, Chodosh LA. The developmental pattern of BRCA1 expression implies a role in differentiation of the breast and other tissues. Nat Genet 11:17-26, 1995
7. Futreal PA, Liu Q, Shattuck-Eidens D, Cochran C, Harshman K, Tavtigian S, Bennett LM, Haugen-Strano A, Swensen J, Miki Y, et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science 266:120-122, 1994
8. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66-71, 1994
9. Chen Y, Chen CF, Riley DJ, Allred DC, Chen PL, Von-Hoff D, Osborne CK, Lee WH. Aberrant subcellular localization of BRCA1 in breast cancer. Science 270:789-791, 1995
10. Sherr CJ. Mammalian G1 cyclins and cell cycle progression. Proc Assoc Am Physicians 107:181-186, 1995
11. Williamson EA, Dadmanesh F, Koeffler H. BRCA1 transactivates the cyclin-dependent kinase inhibitor p27(Kip1). Oncogene 21:3199-3206, 2002
12. Nielsen NH, Emdin SO, Cajander J, Landberg G. Deregulation of cyclin E and D1 in breast cancer is associated with inactivation of the retinoblastoma protein. Oncogene 14:295-304, 1997
13. van Diest PJ, Michalides RJ, Jannink L, van der Valk P, Peterse HL, de Jong JS, Meijer CJ, Baak JP. Cyclin D1 expression in invasive breast cancer. Correlations and prognostic value. Am J Pathol 150:705-711, 1997
14. Geng Y, Whoriskey W, Park MY, Bronson RT, Medema RH, Li T, Weinberg RA, Sicinski P. Rescue of cyclin D1 deficiency by knocking cyclin E. Cell 97:767-777, 1999
15. Nielsen NH, Arnerlov C, Emdin SO, Landberg G. Cyclin E overexpression, a negative prognostic factor in breast cancer with strong correlation to oestrogen receptor status. Br J Cancer 74:874-880, 1996
16. kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nature Med 3:222-225, 1997
17. Fantl V, Smith R, Brookes S, Dickson C, Peters G. Chromosome 11q13 abnormalities in human breast cancer [see comments]. Cancer Surv 18:77-94, 1993
18. Sicinski P, Weinberg RA. A specific role for cyclin D1 in mammary gland development. J Mammary Gland Biol Neoplasia 2:335-342, 1997
19. Elston CW, Ellis IO, Parham DM. Method for grading breast cancer [5]. J Clin Pathol 46:189-190, 1993
20. Pertschuk LP, Feldman JG, Kim YD, Braithwaite L, Schneider F, Braverman AS, Axiotis C. Estrogen receptor immunocytochemistry in paraffin embedded tissues with ER1D5 predicts breast cancer endocrine response more accurately than H222Spgamma in frozen sections or cytosol-based ligand-binding assays. Cancer 77:2514-2519, 1996
21. Donnellan R, Kleinschmidt I, Chetty R. Cyclin E immunoexpression in breast ductal carcinoma: Pathologic correlations and prognostic implications. Hum Pathol 32:89-94, 2001
22. De Potter CR, Quatacker J, Maertens G, Van Daele S, Pauwels C, Verhofstede C, Eechaute W, Roels H. The subcellular localization of the neu protein in human normal and neoplastic cells. Int J Cancer 44:969-974, 1989
23. Styles JM, Harrison S, Gusterson BA, Dean CJ. Rat monoclonal antibodies to the external domain of the product of the C-erbB-2 proto-oncogene. Int J Cancer 45:320-324, 1990
24. Miyamoto K, Fukutomi T, Asada K, Wakazono K, Tsuda H, Asahara T, Sugimura T, Ushijima T. Promoter hypermethylation and post-transcriptional mechanisms for reduced BRCA1 immunoreactivity in sporadic human breast cancers. Jpn J Clin Oncol 32:79-84, 2002
25. Elledge RM, Ciocca DR, Langone G, McGuire WL. Estrogen receptor, progesterone receptor, and HER-2/neu protein in breast cancers from pregnant patients [see comments]. Cancer 71:2499-2506, 1993
26. Ishida T, Yokoe T, Kasumi F, Sakamoto G, Makita M, Tominaga T, Simozuma K, Enomoto K, Fujiwara K, Nanasawa T. Clinicopathologic characteristics and prognosis of breast cancer patients associated with pregnancy and lactation: analysis of case-control study in Japan. Jpn J Cancer Res 83:1143-1149, 1992
27. Lovekin C, Ellis IO, Locker A, Robertson JF, Bell J, Nicholson R, Gullick WJ, Elston CW, Blamey RW. cerbB-2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer 63:439-443, 1991
28. Thorpe SM, Rose C, Rasmussen BB, Mouridsen HT, Bayer T, Keiding N. Prognostic value of steroid hormone receptors: Multivariate analysis of systemically untreated patients with node negative primary breast cancer. Cancer Res 47:6126-6133, 1987
29. Fisher ER, Anderson S, Redmond C, Fisher B. Pathologic findings from the National Surgical Adjuvant Breast Project protocol B-06. Ten-year pathologic and clinical prognostic discriminants. Cancer 71:2507-2514, 1993
30. Yang Q, Sakurai T, Mori I, Yoshimura G, Nakamura M, Nakamura Y, Suzuma T, Tamaki T, Umemura T, Kakudo K. Prognostic significance of BRCA1 expression in Japanese sporadic breast carcinomas. Cancer 92:54-60, 2001
31. Yoshikawa K, Honda K, Inamoto T, Shinohara H, Yamauchi A, Suga K, Okuyama T, Shimada T, Kodama H, Noguchi S, Gazdar AF, Yamaoka Y, Takahashi R. Reduction of BRCA1 protein expression in Japanese sporadic breast carcinomas and its frequent loss in BRCA1-associated cases. Clin Cancer Res 5:1249-1261, 1999
32. Bogdani M, Teugels E, De-Greve J, Bourgain C, Neyns B, Pipeleers-Marichal M. Loss of nuclear BRCA1 localization in breast carcinoma is age dependent. Virchows Arch 440:274-279, 2002
33. Thompson ME, Jensen RA, Obermiller PS, Page DL, Holt JT. Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat Genet 9:444-450, 1995
34. Bernard-Gallon DJ, Dechelotte P, Rio PG, Bignon YJ. Expression of human BRCA1 and BRCA2 proteins in lung from a fetus at 19 weeks' gestation. Int J Cancer 82:771-773, 1999
35. Chen CF, Li S, Chen Y, Chen PL, Sharp ZD, Lee WH. The nuclear localization sequences of the BRCA1 protein interact with the importin-alpha subunit of the nuclear transport signal receptor. J Biol Chem 271:32863-32868, 1996
36. Jernstrom H, Lerman C, Ghadirian P, Lynch HT, Weber B, Garber J, Daly M, Olopade OI, Foulkes WD, Warner E, Brunet JS, Narod SA. Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2. Lancet 354:1846-1850, 1999
37. Xu X, Wagner KU, Larson D, Weaver Z, Li C, Ried T, Hennighausen L, Wynshaw-Boris A, Deng CX. Conditional mutation of BRCA1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat Genet 22:37-43, 1999
38. Langston AA, Malone KE, Thompson JD, Daling JR, Ostrander EA. BRCA1 mutations in a population based sample of young women with breast cancer [see comments]. N Engl J Med 334:137-142, 1996
39. Malone KE, Daling JR, Thompson JD, O'Brien CA, Francisco LV, Ostrander EA. BRCA1 mutations and breast cancer in the general population: Analyses in women before age 35 years and in women before age 45 years with first-degree family history [see comments]. JAMA 279:922-929, 1998
40. Kip1 protein: Prognostic implications in primary breast cancer. Nature Med 3:227-230, 1997
41. Tsuchiya A, Zhang GJ, Kanno M. Prognostic impact of cyclin-dependent kinase inhibitor p27kip1 in node-positive breast cancer. J Surg Oncol 70:230-234, 1999
42. Nohara T, Ryo T, Iwamoto S, Gon G, Tanigawa N. Expression of cell-cycle regulator p27 is correlated to the prognosis and ER expression in breast carcinoma patients. Oncology 60:94-100, 2001
43. Barbareschi M, van-Tinteren H, Mauri FA, Veronese S, Peterse H, Maisonneuve P, Caffo O, Scaioli M, Doglioni C, Galligioni E, Dalla-Palma P, Michalides R. p27(kip1) expression in breast carcinomas: An immunohistochemical study on 512 patients with long-term follow-up. Int J Cancer 89:236-241, 2000
44. Polyak K, Lee MH, Erdjument B, Koff A, Roberts JM, Tempst P, Massague J. Cloning of p27Kip1, a cyclin dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78:59-66, 1994
45. Cariou S, Donovan JC, Flanagan WM, Milic A, Bhattacharya N, Slingerland JM. Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells. Proc Natl Acad Sci USA 97:9042-9046, 2000
46. Tan P, Cady B, Wanner M, Worland P, Cukor B, Magi GC, Lavin P, Draetta G, Pagano M, Loda M. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. Cancer Res 57:1259-1263, 1997
47. Leong AC, Hanby AM, Potts HW, Tan DS, Skilton D, Ryder K, Harris WH, Liebmann RD, Barnes DM, Gillett CE. Cell cycle proteins do not predict outcome in grade I infiltrating ductal carcinoma of the breast. Int J Cancer 89:26-31, 2000
48. Keyomarsi K, O'Leary N, Molnar G, Lees E, Fingert HJ, Pardee AB. Cyclin E, a potential prognostic marker for breast cancer. Cancer Res 54:380-385, 1994
49. Gillett C, Fantl V, Smith R, Fisher C, Bartek J, Dickson C, Barnes D, Peters G. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res 54:1812-1817, 1994
50. Gillett C, Smith P, Gregory W, Richards M, Millis R, Peters G, Barnes D. Cyclin D1 and prognosis in human breast cancer. Int J Cancer 69:92-99, 1996
51. Umekita Y, Ohi Y, Sagara Y, Yoshida H. Overexpression of cyclinD1 predicts for poor prognosis in estrogen receptor-negative breast cancer patients. Int J Cancer 98:415-418, 2002
52. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712, 1989
53. Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T. The product of the human c-erbB-2 gene: A 185-kilodalton glycoprotein with tyrosine kinase activity. Science 232:644-646, 1986
54. Neve RM, Sutterluty H, Pullen N, Lane HA, Daly JM, Krek W, Hynes NE. Effects of oncogenic ErbB-2 on G1 cell cycle regulators in breast tumour cells. Oncogene 19:1647-1656, 2000
55. Hulit J, Lee RJ, Russell RG, Pestell RG. ErbB-2-induced mammary tumor growth: The role of cyclin D1 and p27Kip1. Biochem Pharmacol 64:827-836, 2002
56. Yu Q, Geng Y, Sicinski P. Specific protection against breast cancers by cyclin D1 ablation. Nature 411:1017-1021, 2001
57. Bowe DB, Kenney NJ, Adereth Y, Maroulakou IG. Suppression of Neu-induced mammary tumor growth in cyclin D1-deficient mice is compensated for by cyclin E. Oncogene 21:291-298, 2002
58. Lee RJ, Albanese C, Fu M, D'Amico M, Lin B, Watanabe G, Haines GK, Siegel PM, Hung MC, Yarden Y, Horowitz JM, Muller WJ, Pestell RG. Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway. Mol Cell Biol 20:672-683, 2000
59. Bertheau P, Steinberg SM, Merino MJ. C-erbB-2, p53, and nm23 gene product expression in breast cancer in young women: Immunohistochemical analysis and clinicopathologic correlation. Hum Pathol 29:323-329, 1998
60. Borg A, Tandon AK, Sigurdsson H, Clark GM, Ferno M, Fuqua SA, Killander D, McGuire WL. HER-2/neu amplification predicts poor survival in nodepositive breast cancer. Cancer Res 50:4332-4337, 1990
61. Gusterson BA, Gullick WJ, Venter DJ, Powles TJ, Elliott C, Ashley S, Tidy A, Harrison S. Immunohistochemical localization of c-erbB-2 in human breast carcinomas. Mol Cell Probes 1:383-391, 1987